Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | VNN1 | O95497 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299048 | 0.86 | NPC1 (0.55) | RAB9AGSK3BNPC1HTTL3MBTL1 | |
| SCHEMBL9661934 | 0.83 | RAB9A (0.66) | RAB9ANPC1PTPN1ALDH1A1HTT | |
| SCHEMBL5379828 | 0.78 | RAB9A (0.59) | RAB9AVNN1GSK3BNPC1PTPN1 | |
| SCHEMBL17501399 | 0.77 | EGLN1 (0.47) | ALDH1A1HTTL3MBTL1 | |
| SCHEMBL3195037 | 0.75 | RAB9A (0.56) | RAB9AVNN1GSK3BNPC1PTPN1 | |
| SCHEMBL2308798 | 0.75 | MBOAT4 (0.40) | GSK3BALDH1A1L3MBTL1 | |
| SCHEMBL19367865 | 0.75 | GSK3B (0.59) | RAB9AVNN1GSK3BNSD2EPHX2 | |
| SCHEMBL31399246 | 0.73 | GRM5 (0.47) | RIPK3ALDH1A1HTTL3MBTL1 | |
| SCHEMBL10906842 | 0.73 | RAB9A (0.65) | RAB9ANPC1PTPN1ALDH1A1HTT | |
| SCHEMBL2932069 | 0.73 | RAB9A (0.65) | RAB9ANPC1PTPN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0508469-A1 | 3,4,N-Trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides | DOWELANCO (US) | 1992-10-14 | — | — | EP | claimed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1157025-B1 | PYRAZOLOPYRIDINES | GLAXO GROUP LTD (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1372642-A1 | USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1311507-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-21 | — | — | EP | disclosed |
| US-6498166-B1 | POTENT AND SELECTIVE INHIBITORS OF CYCLOOXYGENASE-2; TREATING PAIN, FEVER AND INFLAMMATION | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| WO-2002078701-A1 | USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| EP-1157025-A1 | PYRAZOLOPYRIDINES | GLAXO GROUP LIMITED (GB) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000052008-A1 | PYRAZOLOPYRIDINES | GLAXO GROUP LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | RAB9A 661/4885VNN1 4804/4885GSK3B 326/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | RAB9A 3472/4885VNN1 689/4885GSK3B 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.